Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Tao Zheng 1 Article
Diabetes Medication Use in Association with Survival among Patients of Breast, Colorectal, Lung, or Gastric Cancer
Michelle L. Baglia, Yong Cui, Tao Zheng, Gong Yang, Honglan Li, Mingrong You, Liling Xu, Harvey Murff, Yu-Tang Gao, Wei Zheng, Yong-Bing Xiang, Xiao-Ou Shu
Cancer Res Treat. 2019;51(2):538-546.   Published online July 2, 2018
DOI: https://doi.org/10.4143/crt.2017.591
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Studies suggest that regular use of metformin may decrease cancer mortality. We investigated the association between diabetes medication use and cancer survival.
Materials and Methods
The current study includes 633 breast, 890 colorectal, 824 lung, and 543 gastric cancer cases identified from participants of two population-based cohort studies in Shanghai. Information on diabetes medication use was obtained by linking to electronic medical records. The associations between diabetes medication use (metformin, sulfonylureas, and insulin) and overall and cancer-specific survival were evaluated using time-dependent Cox proportional hazards models.
Results
After adjustment for clinical characteristics and treatment factors, use of metformin was associated with better overall survival among colorectal cancer patients (hazards ratio [HR], 0.55; 95% confidence interval [CI], 0.34 to 0.88) and for all four types of cancer combined (HR, 0.75; 95% CI, 0.57 to 0.98). Ever use of insulin was associated with worse survival for all cancer types combined (HR, 1.89; 95% CI, 1.57 to 2.29) and for the four cancer types individually. Similar associations were seen for diabetic patients. Sulfonylureas use was associated with worse overall survival for breast or gastric cancer (HR, 2.87; 95% CI, 1.22 to 6.80 and HR, 2.05; 95% CI, 1.09 to 3.84, respectively) among diabetic patients. Similar association patterns were observed between diabetes medication use and cancer-specific survival.
Conclusion
Metformin was associated with improved survival among colorectal cancer cases, while insulin use was associated with worse survival among patients of four major cancers. Further investigation on the topic is needed given the potential translational impact of these findings.

Citations

Citations to this article as recorded by  
  • Effect of Metformin Use on Survival and Recurrence Rate of Gastric Cancer After Gastrectomy in Diabetic Patients: A Systematic Review and Meta-analysis of Observational Studies
    Mansour Bahardoust, Safa Mousavi, Zahra Deylami Moezi, Mohsen Yarali, Ali Tayebi, Faranak Olamaeian, Adnan Tizmaghz
    Journal of Gastrointestinal Cancer.2024; 55(1): 65.     CrossRef
  • Antidiabetic Drugs in Breast Cancer Patients
    Wojciech Garczorz, Agnieszka Kosowska, Tomasz Francuz
    Cancers.2024; 16(2): 299.     CrossRef
  • Association of metformin and statin uses with the prognosis of colon cancer: a meta-analysis
    Yanyan Xu, Hao Che, Jiang Liu, Pingjiang Ye
    European Journal of Cancer Prevention.2024; 33(5): 414.     CrossRef
  • Metformin in combination with chemotherapy increases apoptosis in gastric cancer cells and counteracts senescence induced by chemotherapy
    Katia Vázquez‑Ibarra, Josefina Sánchez López, Tomás Pineda Razo, José Cruz Lozano, Brenda Ortiz‑Tamayo, Luis Palafox‑Mariscal, Rosa González Arreola, Juan González‑García, Pablo Ortiz-Lazareno
    Oncology Letters.2024;[Epub]     CrossRef
  • A Mathematical Model of the Disruption of Glucose Homeostasis in Cancer Patients
    Noah Salentine, Jonathan Doria, Chinh Nguyen, Gabriella Pinter, Shizhen Emily Wang, Peter Hinow
    Bulletin of Mathematical Biology.2023;[Epub]     CrossRef
  • Effect of Metformin on the Prognosis of Gastric Cancer Patients with Type 2 Diabetes Mellitus: A Meta-Analysis Based on Retrospective Cohort Studies
    Lingna Li, Jianing Huang, Tongmin Huang, Jie Yao, Yeyuan Zhang, Meiling Chen, Haojie Shentu, Haiying Lou, Flavia Prodam
    International Journal of Endocrinology.2023; 2023: 1.     CrossRef
  • Shared Lifestyle-Related Risk Factors of Cardiovascular Disease and Cancer: Evidence for Joint Prevention
    Farzad Masoudkabir, Noushin Mohammadifard, Arya Mani, Andrew Ignaszewski, Margot K. Davis, Golnaz Vaseghi, Marjan Mansourian, Christopher Franco, Carolyn Gotay, Nizal Sarrafzadegan, Francesco Giallauria
    The Scientific World Journal.2023; 2023: 1.     CrossRef
  • Diabetes Mellitus and Gastric Cancer: Correlation and Potential Mechanisms
    Li Wang, Zhe Zhang, Eusebio Chiefari
    Journal of Diabetes Research.2023; 2023: 1.     CrossRef
  • Perspectives of metformin use in endometrial cancer and other gynaecological malignancies
    Bartłomiej Barczyński, Karolina Frąszczak, Jan Kotarski
    Journal of Drug Targeting.2022; 30(4): 359.     CrossRef
  • Type 2 Diabetes and all-cause mortality among Spanish women with breast cancer
    L. Fernández-Arce, N. Robles-Rodríguez, A. Fernández-Feito, A. Llaneza-Folgueras, A. I. Encinas-Muñiz, A. Lana
    Cancer Causes & Control.2022; 33(2): 271.     CrossRef
  • Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications
    Guan-Hua Yu, Shuo-Feng Li, Ran Wei, Zheng Jiang, Eusebio Chiefari
    Journal of Diabetes Research.2022; 2022: 1.     CrossRef
  • Systemic Evaluation of the Effect of Diabetes Mellitus on Breast Cancer in a Mouse Model
    Nana Wei, Jinmiao Lu, Zhibing Lin, Xiaoyu Wang, Mengmeng Cai, Shengyao Jiang, Xiaoyu Chen, Shilan Zhu, Dong Zhang, Li Cui
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The Association of Metformin, Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes: A Retrospective Cohort Study
    Sami Erkinantti, Ari Hautakoski, Reijo Sund, Martti Arffman, Elina Urpilainen, Ulla Puistola, Esa Läärä, Arja Jukkola, Peeter Karihtala
    Biomolecules.2022; 12(9): 1301.     CrossRef
  • Metformin protects against diabetes-induced heart injury and dunning prostate cancer model
    BB Bayrak, P Koroglu, O Karabulut Bulan, R Yanardag
    Human & Experimental Toxicology.2021; 40(2): 297.     CrossRef
  • Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy
    Alejandro Schcolnik-Cabrera, Alma Chavez-Blanco, Guadalupe Dominguez-Gomez, Mandy Juarez, Ariana Vargas-Castillo, Rafael Isaac Ponce-Toledo, Donna Lai, Sheng Hua, Armando R. Tovar, Nimbe Torres, Delia Perez-Montiel, Jose Diaz-Chavez, Alfonso Duenas-Gonzal
    Scientific Reports.2021;[Epub]     CrossRef
  • Repurposing metformin for the treatment of gastrointestinal cancer
    Ademar Dantas Cunha Júnior, Arinilda Campos Bragagnoli, Felipe Osório Costa, José Barreto Campello Carvalheira
    World Journal of Gastroenterology.2021; 27(17): 1883.     CrossRef
  • Improved prognosis in gastric adenocarcinoma among metformin users in a population-based study
    Jiaojiao Zheng, Giola Santoni, Shao-Hua Xie, Jesper Lagergren
    British Journal of Cancer.2021; 125(2): 277.     CrossRef
  • The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature
    Chin-Hsiao Tseng
    Biomolecules.2021; 11(7): 1022.     CrossRef
  • Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study
    Byoung Hyuck Kim, Moon-June Cho, Jeanny Kwon
    International Journal of Clinical Oncology.2021; 26(11): 2004.     CrossRef
  • Progress in understanding of relationship between diabetes and colorectal cancer
    Guan-Hua Yu, Zheng Jiang
    World Chinese Journal of Digestology.2021; 29(23): 1323.     CrossRef
  • The effect of metformin on gastric cancer in patients with type 2 diabetes: a systematic review and meta-analysis
    Y. Shuai, C. Li, X. Zhou
    Clinical and Translational Oncology.2020; 22(9): 1580.     CrossRef
  • The right place for metformin today
    Guntram Schernthaner, Gerit-Holger Schernthaner
    Diabetes Research and Clinical Practice.2020; 159: 107946.     CrossRef
  • Suppressive effects of metformin on colorectal adenoma incidence and malignant progression
    Min Deng, Siqin Lei, Dongdong Huang, Hui Wang, Shuli Xia, Enping Xu, Yihua Wu, Honghe Zhang
    Pathology - Research and Practice.2020; 216(2): 152775.     CrossRef
  • Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend


    Jing Zhang, Liping Wen, Quan Zhou, Kuifeng He, Lisong Teng
    Cancer Management and Research.2020; Volume 12: 8545.     CrossRef
  • Does Roux-en-Y Construction Really Bring Benefit of Type 2 Diabetes Mellitus Remission After Gastrectomy in Patients with Gastric Cancer? A Systematic Review and Meta-Analysis
    Dong Peng, Yu-Xi Cheng, Wei Zhang
    Diabetes Therapy.2020; 11(12): 2863.     CrossRef
  • Prognosis of Patients with Colorectal Cancer with Diabetes According to Medication Adherence: A Population-Based Cohort Study
    Sunho Choe, Joonki Lee, Ji Won Park, Seung-Yong Jeong, Young Min Cho, Byung-Joo Park, Aesun Shin
    Cancer Epidemiology, Biomarkers & Prevention.2020; 29(6): 1120.     CrossRef
  • The combination of orlistat, lonidamine and 6‑diazo‑5‑oxo‑L‑norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells
    Alejandro Schcolnik‑Cabrera, Alma Chavez‑Blanco, Guadalupe Dominguez‑Gomez, Mandy Juarez, Donna Lai, Sheng Hua, Armando Tovar, Jose Diaz‑Chavez, Alfonso Duenas‑Gonzalez
    Oncology Letters.2020; 20(3): 3053.     CrossRef
  • Diabetes Mellitus and Colon Carcinogenesis: Expectation for Inhibition of Colon Carcinogenesis by Oral Hypoglycemic Drugs
    Junichi Kato, Yohei Shirakami, Masahito Shimizu
    Gastrointestinal Disorders.2019; 1(2): 273.     CrossRef
  • Use of Antihypertensive Medications and Survival Rates for Breast, Colorectal, Lung, or Stomach Cancer
    Yong Cui, Wanqing Wen, Tao Zheng, Honglan Li, Yu-Tang Gao, Hui Cai, Mingrong You, Jing Gao, Gong Yang, Wei Zheng, Yong-Bing Xiang, Xiao-Ou Shu
    American Journal of Epidemiology.2019; 188(8): 1512.     CrossRef
  • Effects of propofol and sevoflurane on blood glucose, hemodynamics, and inflammatory factors of patients with type�2 diabetes mellitus and gastric cancer
    Jinhui Liu, Li Yang
    Oncology Letters.2019;[Epub]     CrossRef
  • A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer
    Audrius Dulskas, Ausvydas Patasius, Donata Linkeviciute-Ulinskiene, Lina Zabuliene, Giedre Smailyte
    Aging.2019; 11(17): 7197.     CrossRef
  • 10,508 View
  • 263 Download
  • 37 Web of Science
  • 31 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP